Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5668_Библиотеки_им_академика_М_И_Перельмана
.pdf
16 18F-FES
https://t.me/med1917
277
16.4 Clinical Indications
16.4.1 Predictive andPrognostic
Biomarker
[18F]-FES has been demonstrated to distinguish
tumors with intrinsically good or poor prognosis,
alone [35, 36] or in combination with [18F]-FDG
[37–39], and to determine which therapies could
be effective in which patients [35, 37, 38, 40–55].
Measurements of SUVmax of [18F]-FES PET/CT
serial images could be used to predict the patient
progression-free survival (PFS) receiving ER
antagonist therapy, such as fulvestrant [35, 46].
While the combination of [18F]-FES and
[18F]-FDG is shown to be particularly useful in
identifying ER heterogeneity in BC bone metastases, which signicantly associated with survival. Moreover, the extension of the FDG-avid
component correlates with the risk of disease
progression [39]. The most important clinical
impact is the ability of [18F]-FES to predict
patients who can be treated successfully by hormonal therapies. Despite ER+ breast cancer on
IHC, most of the patients respond to rst-line
hormonal therapies, and less than half respond to
second- or third-line hormonal therapies [41].
Only a functional ER able to bind estrogen
ligand, visualizable using [18F]-FES as PET
radiotracer, is a good predictive biomarker [43].
Several studies have demonstrated the predictivity of this radiotracer for selecting patients that
will benet from different kinds of therapies,
such as unspecic hormonal and chemotherapy
[
43] or tamoxifen and hormonal therapies fol-
lowing progression on tamoxifen [44, 45]. Also,
in the case of novel hormonal therapies, such as
SERDs (fulvestrant), which degrade ER and thus
block estrogen binding to ER, aromatase inhibitors (AI), which block estrogen production, and
cyclin-dependent kinase (CDK) 4/6 inhibitors,
which block downstream ER effects, [18F]-FES
seems to be a good predictive biomarker. The
results of Fig.16.6 show how only a three-way
PET classier ([18F]-FES heterogeneous,
Fig. 16.6a, low [18F]-(FES/FDG) and high
[18F]-(FES/FDG) groups, Fig. 16.6b) remained
the only independent, statistically signicant
prognostic factor for PFS (Fig.
with ER-positive metastatic breast cancer under
fulvestrant therapy [56].
16.6c) in patients
16.4.2 ER Assessment
In France, the [18F]-FES is approved for the
whole-body evaluation of recurrent ER-positive
breast cancer in place of biopsy [17]. While the
FDA strongly encourages bioptic conrmation of
[18F]-FES PET ndings, in line with prevailing
practices that biopsy is the best practice for treatment whenever possible (5). However, in the case
of the brain or deep osseous spinal lesions where
the biopsy is difcult, impossible, or only possible with substantial risks, the use of [18F]-FES to
assess a functional ER is very useful. Bonapati
[57] et al. reported how in two representative
cases the use of [18F]-FES PET/CT improves the
detection of intraorbital metastases in ER-positive
BC (Fig.16.7a, b). Abnormal intense [18F]-FES
activity in the right posterior orbit (A, arrow) and
normal physiologic 18F-FDG activity in the right
extraocular muscles (B, arrow). Adopted from
[57].
16.4.3 Problem-Solving Clinical
Dilemmas
In a recent retrospective study, Boers [58] etal.
investigated the value of [
management of clinical dilemmas in BC patients,
not solvable with standard workup. They analyzed 100 scans performed on 83 patients in
Groningen between 2009 and 2019. The clinical
dilemma, as described in Table16.1, was solved
in 87 of 100 scans (87%). Most of the frequency
of solved dilemmas was related to whether scans
were 18F-FES–positive (n=63) or [18F]-FES negative (n=37; P<0.001) rather than to itself clini-
cal dilemma category (P=0.334) [58].
Similar results were reported [59–61] using
[18F]-FES to solve a clinical dilemma in the case
of inconclusive results from other diagnostic
studies. Even if van Kruchten etal. found FES
PET solved clinical problems and led to therapy
18
F]-FES PET in the
278
a
b
Months
https://t.me/med1917
F-FDG
18
M. R. Ruggiero et al.
P < 0.001
Heterogeneous group (n = 12)Low FES/FDG (n = 11)
High FES/FDG (n = 12)
F]-FES/FDG SUVmax (0.96); (c) Kaplan–
18
F]-FES positive metastatic lesions were divided
18
010203040
1. 0
0.8
0.6
0.4
0.2
0.0
c
progression-free survival (proportion)
Meier curves of PFS stratied by the three classications groups. (Adopted and modi-
ed from [56])
group. Patients with 100% of the [
into two groups by the median ratio of [
F-FDG
18
Heterogeneous group
F]-(FES/FDG)
18
F-FES
18
F-FES
18
F-FDG
18
F]-FES.His PFS was 3.7months with any clinical
18
F]-FES positive and negative lesions. The left rib shows signicant
18
F]-FDG but not on [
18
F-FES
18
Low FES/FDG High FES/FDG
uptake on [
Fig. 16.6 (a) Representative cases of a heterogeneous group. A 50-year-old female
patient has both [
benet from fulvestrant treatment; (b) representative cases of the [
ab
16 18F-FES
https://t.me/med1917
Fig. 16.7 Abnormal intense [18F]-FES activity in the right posterior orbit (a, arrow) and normal physiologic [18F]-FDG
activity in the right extraocular muscles (b, arrow). (Adopted from [57])
279
Table 16.1
performed on BC patients [
The clinical dilemma category was modied
from the original paper [58]
Inability to determine the extent of
metastatic disease or suspected metastatic
disease with the standard workup
Unclear ER status of the tumor 31
Inability to determine which primary
tumor caused the metastases
The clinical dilemma category in 100 scans
58]
Number of
cases
52
17
comparison of the performance of both
radiotracers [18F]-FES PET and [18F]-FDG
PET.Figure16.8 is an example of this comparison [62]. Some studies demonstrated not only
comparable sensitivities [62–64] but also the
change in clinical management in 26% of patients
[64]. A retrospective analysis of six prospective
trials where [18F]-FES and [18F]-FDG PET were
performed in close relation identied patients
with invasive lobular breast cancer (ILC) as a
changes in 48% of patients, the detection of liver
metastases by [18F]-FES PET was poor conrm-
subset of ER-positive breast cancer where FES
PET compared favorably to FDG PET [
ing the biggest issue of the use of FES in clinical
practice [59].
16.4.5 Correlation ER-Targeted
18
Therapeutics and[
F]-FES
16.4.4 Systemic Staging
In the era of improving personalized medicine the
There are ongoing prospective clinical trials of
[18F]-FES PET for the staging of ER-positive
breast cancer in Europe (Clinicaltrialsregister.
EU) and the USA (ClinicalTrials.gov). Current
standard-of-care imaging for systemic staging of
breast cancer is CT/bone scan and the FDG PET/
CT.So, the aim of most ongoing projects is the
use of [18F]-FES PET not only to assess ER blockade in patients on ER antagonists, especially in
patients who fail to respond, but also in the early
stages of drug development is increasing and many
groups reported the success of this paradigm.
In 2011, Linden etal. evaluated estrogen binding
changes in patients with metastatic ER-positive BC
65].
280
https://t.me/med1917
M. R. Ruggiero et al.
a b
c
d
e
Fig. 16.8 [18F]-FDG and [18F]-FES PET/CT images of a
46-year-old female with lobular carcinoma and histologically conrmed ER-positive recurrence in the left axillary
level II lymph node (Allred score=8). Maximum intensity projection (a) and transaxial [
show equivocal uptake in the left axillary lymph node
18
F]-FDG images (b–e)
after different kinds of endocrine therapy [48], such
as the receptor blocking agents (tamoxifen and fulvestrant) and aromatase inhibitors. The [18F]-FES
SUV (dened as [18F]-FES SUV≤1.5) allowed to
discriminate between complete and uncomplete
tumor ER blockade [48]. Indeed, Van Kruchten
et al. determined the fulvestrant dose needed to
abolish ER binding of estrogen ligands using
[18F]-FES [46]. In a multicenter phase I trial, the
biologic effective dose (BED) of a novel ER-targeted
was determined using [18F]-FES [66]. They hypothesized that the coupling of optimal dose and maximum
pharmacologic effect could best assess ER
blockade through baseline and post-therapy imaging. In early-phase, clinical trials of novel
ER-targeting therapeutics, the use of [18F]-FES PET
has now become common to successfully determine the BED for multiple agents [67–69].
f
g
h
i
j
(arrows) and physiologic bone uptake in the thoracic spine
(dotted arrows). However, positive [
seen in the axillary lymph nodes (f–h; arrows) and the rst
thoracic vertebra (f, i, j; dotted arrows). (Adopted from
62])
[
18
F]-FES uptake is
cers, such as uterine cancers. It is well known that
18
the uptake of [
F]-FES and [18F]-FDG is especially useful for the differential diagnosis of endometrial hyperplasia in low-grade and high- grade
endometrial cancer. In particular, the characteristics of low-grade endometrial carcinomas are
decreased uptake of [18F]-FES, increased uptake
of [18F]-FDG, with an increased ratio of [18F]-FDG
to [18F]-FES uptake [70, 71]. On the opposite
high-grade carcinomas show an increased
[18F]-FDG to [18F]-FES uptake ratio. In the same
manner, malignant uterine sarcomas demonstrate
18
lower [
F]-FES uptake and a higher [18F]-FDG to
[18F]-FES uptake ratio allowing differentiation
between benign uterine leiomyomas and malignant uterine sarcomas [72, 73]. Additionally, other
studies show the use of [18F]-FES to imaging the
majority of ovarian cancers that express ER
[74–76].
16.4.6 Utilization of18F-FES inOther
Populations
As analogous to estradiol, [18F]-FES PET can use
as a PET radiotracer for other ER-expressing can-
16.5 Clinical Cases
Case 1 [77] (Fig.16.9)
Case 2 [78] (Fig.16.10)
16 18F-FES
https://t.me/med1917
281
Fig. 16.9 A 73-year-old female underwent lymphatic
node ultrasonography, and core-needle biopsy showed
carcinoma invasive NST G1 (Ki67 1%), ER (3+) 100%,
and HER-2 negative in both breasts. PET/CT with 18FFES showed pathological uptakes in both breast tumors,
but lymph node packages in the left axilla and enlarged
cervical nodes were not estrogen-positive metastasis from
breast cancer. Therefore, a core-needle biopsy of the left
axilla lymph node was done with the result of DLBCL
Ki67 90%. For DLBCL staging, PET/CT with [
18
F]-FDG
was performed. The pathological uptakes were present in
the left axilla tumor and enlarged cervical nodes. In this
case, PET/CT with [
18
F]-FDG and [18F]-FES performed
along with FNA or core-needle biopsy allows for establishing the right diagnosis and the stage of both diseases.
Case 1 [77]
282
https://t.me/med1917
M. R. Ruggiero et al.
Fig. 16.10 A 64-year-old female with multiple metastases from breast cancer showed the same degree of accumulation of [
lymphadenopathy, whereas higher 18F-FES uptake than
18
[
F]-FDG uptake was detected in right supraclavicular
lymphadenopathy. In patients with multiple metastases
from breast cancer, the combination of [
18
[
F]-FDG-PET imaging studies has the potential to reect
18
F]-FDG as [18F]-FES in left hilar
16.6 PET/CT Acquisition Protocol
Prior recommendations for [18F]-FES use can be
found in Venema etal. [79] and Kurland et al.
[80]. Thus prescribing information is available
from the FDA label [18]. Before administering
[18F]-FES, it is important to conrm the patient is
18
F]-FES and
tumor heterogeneity and characterize the in vivo tumor
phenotype. The index of the [
ratio could be used as a determinant of hormonal therapies
such as tamoxifen and aromatase inhibitor for breast cancer and pregestational agents and gonadotropin-releasing
hormone agonists for gynecological tumors. Case 2 [78]
18
F]-FDG: [18F]-FES SUV
not pregnant and not using selective estrogenic
receptor modulators, such as tamoxifen, or selective estrogenic degraders (SERDs), such as fulvestrant. Current guidelines suggest withdrawal
from tamoxifen for 8weeks and withdrawal from
fulvestrant for 28 weeks. The recommended
administered dose is 111–222MBq of FES (often
16 18F-FES
https://t.me/med1917
185 MBq), administered over 1–2 min. PET
imaging is to begin 20–80 min (often 60min)
after radiopharmaceutical administration.
16.7 Variants andPitfalls
In the clinical practice, the main limitation of the
use of [18F]-FES is hard detection of liver metastases due to high hepatic uptake. Rapid blood
clearance, leading to lower tumoral uptake, and
low selectivity for ERα and ERβ, resulting in
reduced specicity of the procedure, are other
undeniable pitfalls of this radiotracer. For this
reason, additional estradiol analogs have been
developed. Most relevant for the clinical practice
may be radiopharmaceuticals such as 4-uoro11β -methoxy-16α -[18F]-fluoroestradiol
(4FM-[18F]F-FES) [81] and 1-(2-(2-(2-[18F]uoroethoxy)ethoxy)ethyl)-1H-1,2,3-triazoleestradiol ([18F]F-FETE) [82] to improve target
selectivity. As detector of functional ER,
[18F]-FES could not detect unfunctional ER, still
expressed in tumors. Thus, the lower sensitivity
for predicting the response to endocrine therapy
in breast cancer patients is strongly correlated
with [18F]-FES uptake and the degree of stromal
components [40]. Therapy like selective estrogen
receptor modulators or degraders (e.g., SERMs
or SERDs) must be discontinued before the PET
imaging to avoid interference with [18F]-FES
uptake [18].
References
1. Katzenellenbogen JA. The quest for improving the
management of breast cancer by functional imaging: the discovery and development of 16α-[18F]
uoroestradiol (FES), a PET radiotracer for the
estrogen receptor, a historical review. Nucl Med Biol.
2021;92:24–37.
Kiesewetter DO, Katzenellenbogen JA, Kilbourn
2.
MR, Welch MJ. Synthesis of 16-uoroestrogens by
unusually facile uoride ion displacement reactions:
prospects for the preparation of uorine-18 labeled
estrogens. J Org Chem. 1984;49:4900–5.
Kiesewetter DO, Kilbourn MR, Landvatter
3.
SW, Heiman DF, Katzenellenbogen JA, Welch
MJ.Preparation of four Fluorine-18-labeled estrogens
and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212–21.
Brodack JW, Kilbourn MR, Welch MJ,
4.
Katzenellenbogen JA. Application of robotics to
radiopharmaceutical preparation: controlled synthesis
of uorine-18 16 alpha-uoroestradiol-17 beta. J Nucl
Med. 1986;27:714–21.
Lim JL, Zheng L, Berridge MS, Tewson TJ.The use
5.
of 3-methoxymethyl-16β, 17β-epiestriol-O-cyclic
sulfone as the precursor in the synthesis of F-18
16α-uoroestradiol. Nucl Med Biol. 1996;23:911–5.
Römer J, Steinbach J, Kasch H.Studies on the syn-
6.
thesis of 16α-[18F]uoroestradiol. Appl Radiat Isot.
1996;47:395–9.
7.
Mori T, Kasamatsu S, Mosdzianowski C, Welch MJ,
Yonekura Y, Fujibayashi Y.Automatic synthesis of 16
alpha-[(18)F]uoro-17beta-estradiol using a cassettetype [(18)F]uorodeoxyglucose synthesizer. Nucl
Med Biol. 2006;33:281–6.
8.
Oh SJ, Chi DY, Mosdzianowski C, Kil HS, Ryu JS,
Moon DH. The automatic production of 16α-[18F]
uoroestradiol using a conventional [18F]FDG module with a disposable cassette system. Appl Radiat
Isot. 2007;65:676–81.
Kumar P, Mercer J, Doerkson C, Tonkin K, McEwan
9.
AJB. Clinical production, stability studies and PET
imaging with 16-alpha-[18F]uoroestradiol ([18F]
FES) in ER positive breast cancer patients. J Pharm
Pharm Sci. 2007;10:256s–65s.
Knott KE, Grätz D, Hübner S, Jüttler S, Zankl C,
10.
Müller M. Simplied and automatic one-pot synthesis of 16α
performance liquid chromatography purication. J
Label Compd Radiopharm. 2011;54:749–53.
11.
Dixit M, Shi J, Wei L, Afari G, Bhattacharyya
S. Synthesis of clinical-grade [18F]-Fluoroestradiol
as a surrogate PET biomarker for the evaluation of
estrogen receptor-targeting therapeutic drug. Int J Mol
Imaging. 2013;2013:278607.
Kil HS, Cho HY, Lee SJ, Oh SJ, Chi DY.Alternative
12.
synthesis for the preparation of 16α-[18F]
uoroestradiol. J Label Compd Radiopharm.
2013;56:619–26.
Shi J, Afari G, Bhattacharyya S. Rapid synthesis
13.
of [18F]-uoroestradiol: remarkable advantage of
microwaving over conventional heating. J Label
Compd Radiopharm. 2014;57:730–6.
Zhou D, Lin M, Yasui N, Al-Qahtani MH, Dence CS,
14.
Schwarz S, Katzenellenbogen JA. Optimization of
the preparation of uorine-18-labeled steroid receptor ligands 16alpha-[18F]uoroestradiol (FES), [18F]
uoro furanyl norprogesterone (FFNP), and 16beta[18F]uoro-5alpha-dihydrotestosterone (FDHT) as
radiopharmaceuticals. J Label Compd Radiopharm.
2014;57:371–7.
Fedorova O, Nikolaeva V, Krasikova R.Automated
15.
SPE-based synthesis of 16α-[18F]uoroestradiol
without HPLC purication step. Appl Radiat Isot.
2018;141:57–63.
16.
Römer J, Füchtner F, Steinbach J, Johannsen
B. Automated production of 16α-[18F]uoroes-
tradiol for breast cancer imaging. Nucl Med Biol.
1999;26:473–9.
-[18F]uoroestradiol without high-
283
284
https://t.me/med1917
M. R. Ruggiero et al.
17.
ESTROTEP (uoroestradiol (18F)). Haute Aut
Santé.
en/estrotep-
2022.
18.
FDA.Cerianna (Fluoroestradiol F18) Full Prescribing
information. NewYork: Zionexa; 2020.
19.
Jiang X, Li Y, Wang X, etal. Quick automatic synthe-
sis of solvent-free 16α-[18F] Fluoroestradiol: comparison of Kryptox 222 and Tetrabutylammonium
bicarbonate. Front Oncol. 2020;10:10.
Wang M, Glick-Wilson BE, Zheng Q-H. Fully auto-
20.
mated radiosynthesis and quality control of estrogen
receptor targeting radiopharmaceutical 16α-[18F]
uoroestradiol ([18F]FES) for human breast cancer
imaging. Appl Radiat Isot. 2020;160:109109.
Fedorova O, Orlovskaya V, Nadporojskii M,
21.
Krasikova R.Automated synthesis of the 16α-[18F]
uoroestradiol ([18F]FES): minimization of precursor amount and resulting benets. Radiochim Acta.
2020;108:979–88.
Ulaner GA. 16α-18F-uoro-17β-Fluoroestradiol
22.
(FES): clinical applications for patients with breast
cancer. Semin Nucl Med. 2022;52:574–83.
23.
Acheampong T, Kehm RD, Terry MB, etal. Incidence
Trends of Breast Cancer Molecular Subtypes by
Age and Race/Ethnicity in the US From 2010 to
2016. JAMA Netw Open. 2020;3:e2013226.
jamanetwork.com/journals/jamanetworkopen/fullarticle/2769316. Accessed 25 Oct 2022.
24.
Annual Report to the Nation on the Status of Cancer.
1975–2011. Featuring Incidence of Breast Cancer
Subtypes by Race/Ethnicity, Poverty, and StatePMC. https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4603551/. Accessed 25 Oct 2022.
25.
Hwang K-T, Kim J, Jung J, Chang JH, Chai YJ, Oh
SW, Oh S, Kim YA, Park SB, Hwang KR. Impact
of breast cancer subtypes on prognosis of women
with operable invasive breast cancer: a populationbased study using SEER database. Clin Cancer Res.
2019;25:1970–9.
26.
O’Brien SR, Edmonds CE, Katz D, Mankoff DA,
Pantel AR. 18F-Fluoroestradiol (FES) PET/CT:
review of current practice and future directions. Clin
Translat Imaging. 2022;10:331–41.
Lefebvre-Lacœuille C, Lacœuille F, Rousseau C,
27.
Courbon F, Benard F, Couturier O-F. 16α-[18F]-
uoro-17ß-oestradiol ([18F]FES): a biomarker
for imaging oestrogen receptor expression with
positron emission tomography (PET). Méd Nucl.
2015;39:64–70.
28.
Noé G, Cheng YC, Dabiké M, Croxatto HB.Tissue
uptake of human sex hormone-binding globulin and
its inuence on ligand kinetics in the adult female
Rat1. Biol Reprod. 1992;47:970–6.
Hammes A, Andreassen TK, Spoelgen R, etal. Role
29.
of endocytosis in cellular uptake of sex steroids. Cell.
2005;122:751–62.
Peterson LM, Kurland BF, Link JM, Schubert EK,
30.
Stekhova S, Linden HM, Mankoff DA.Factors inuencing the uptake of 18F-uoroestradiol in patients
https://www.has- sante.fr/jcms/p_3161190/
uoroestradiol- 18f. Accessed 26 Oct
https://
with estrogen receptor positive breast cancer. Nucl
Med Biol. 2011;38:969–78.
Mankoff DA, Tewson TJ, Eary JF.Analysis of blood
31.
clearance and labeled metabolites for the estrogen
receptor tracer [F-18]-16α-Fluoroestradiol (FES).
Nucl Med Biol. 1997;24:341–8.
Sundararajan L, Linden HM, Link JM, Krohn KA,
32.
Mankoff DA. 18F-Fluoroestradiol. Semin Nucl Med.
2007;37:470–6.
33.
Mankoff DA, Peterson LM, Tewson TJ, Link
JM, Gralow JR, Graham MM, Krohn KA. [18F]
Fluoroestradiol radiation dosimetry in human PET
studies. J Nucl Med. 2001;42:679–84.
Montagna E, Pirola S, Maisonneuve P, De Roberto G,
34.
Cancello G, Palazzo A, Viale G, Colleoni M.Lobular
metastatic breast cancer patients with gastrointestinal involvement: features and outcomes. Clin Breast
Cancer. 2018;18:e401–5.
He M, Liu C, Shi Q, et al. The predictive value of
35.
early changes in 18F-Fluoroestradiol positron emission tomography/computed tomography during
Fulvestrant 500mg therapy in patients with estrogen
receptor-positive metastatic breast cancer. Oncologist.
2020;25:927–36.
36.
Gong C, Yang Z, Sun Y, etal. A preliminary study
of 18F-FES PET/CT in predicting metastatic breast
cancer in patients receiving docetaxel or fulvestrant
with docetaxel. Sci Rep. 2017;7:6584.
org/10.1038/s41598-
Kurland BF, Peterson LM, Lee JH, Schubert EK,
37.
Currin ER, Link JM, Krohn KA, Mankoff DA,
Linden HM. Estrogen receptor binding (18F-FES
PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy
in patients with ER+ breast cancer. Clin Cancer Res.
2017;23:407–15.
Liu C, Xu X, Yuan H, Zhang Y, Zhang Y, Song
38.
S, Yang Z. Dual tracers of 16α-[18F]uoro-17β
estradiol and [18F]uorodeoxyglucose for prediction
of progressionin patients with HR+/HER2- metastatic breast cancer.
Front Oncol. 2020;10:10.
39.
Bottoni G, Piccardo A, Fiz F, etal. Heterogeneity of
bone metastases as an important prognostic factor in
patients affected by oestrogen receptor-positive breast
cancer. The role of combined [18F]Fluoroestradiol
PET/CT and [18F]Fluorodeoxyglucose PET/CT.Eur
J Radiol. 2021;141:109821.
40.
Takahashi M, Maeda H, Tsujikawa T, Kono H, Mori
T, Kiyono Y, Okazawa H, Noriki S, Imamura Y, Goi
T. 18F-Fluoroestradiol tumor uptake is inuenced
by structural components in breast cancer. Clin Nucl
Med. 2021;46:884–9.
Linden HM, Stekhova SA, Link JM, etal. Quantitative
41.
uoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast
cancer. J Clin Oncol. 2016;24:2793. https://doi.
org/10.1200/JCO.2005.04.3810.
42.
Boers J, Venema CM, de Vries EFJ, Glaudemans
AWJM, Kwee TC, Schuuring E, Martens JWM, Elias
017- 06903- 8.
free survival after Fulvestrant therapy
https://doi.
-
16 18F-FES
https://t.me/med1917
285
SG, Hospers GAP, Schröder CP. Molecular imaging to identify patients with metastatic breast cancer
who benet from endocrine treatment combined with
cyclin-dependent kinase inhibition. Eur J Cancer.
2020;126:11–20.
Mortimer JE, Dehdashti F, Siegel BA,
43.
Katzenellenbogen JA, Fracasso P, Welch MJ.Positron
emission tomography with 2-[18F]uoro-2-deoxy-Dglucose and 16α-[18F]uoro-17β-estradiol in breast
cancer: correlation with estrogen receptor status
and response to systemic therapy. Clin Cancer Res.
1996;2:933–9.
Dehdashti F, Flanagan FL, Mortimer JE,
44.
Katzenellenbogen JA, Welch MJ, Siegel BA.Positron
emission tomographic assessment of “metabolic are”
to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51–6.
Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K,
45.
Katzenellenbogen JA, Welch MJ. Metabolic are:
indicator of hormone responsiveness in advanced
breast cancer. J Clin Oncol. 2001;19:2797–803.
van Kruchten M, de Vries EG, Glaudemans AW, van
46.
Lanschot MC, van Faassen M, Kema IP, Brown M,
Schröder CP, de Vries EF, Hospers GA.Measuring
residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
Cancer Discov. 2015;5:72–81.
47.
Dehdashti F, Mortimer JE, Trinkaus K, Naughton
MJ, Ellis M, Katzenellenbogen JA, Welch MJ, Siegel
BA. PET-based estradiol challenge as a predictive
biomarker of response to endocrine therapy in women
with estrogen-receptor-positive breast cancer. Breast
Cancer Res Treat. 2009;113:509–17.
48.
Linden HM, Kurland BF, Peterson LM, et al.
Fluoroestradiol positron emission tomography
reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients
with metastatic breast cancer. Clin Cancer Res.
2011;17:4799–805.
49.
Peterson LM, Kurland BF, Schubert EK, etal. A phase
2 study of 16α-[18F]-uoro-17β-estradiol positron
emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
Mol Imaging Biol. 2014;16:431–40.
van Kruchten M, Glaudemans AWJM, de Vries EFJ,
50.
Schröder CP, de Vries EGE, Hospers GAP.Positron
emission tomography of tumour [18F]uoroestradiol
uptake in patients with acquired hormone-resistant
metastatic breast cancer prior to oestradiol therapy.
Eur J Nucl Med Mol Imaging. 2015;42:1674–81.
51.
Park JH, Kang MJ, Ahn J-H, etal. Phase II trial of
neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and
human epidermal growth factor receptor 2 (HER2)positive breast cancer [neo-ALL-IN]: highlighting the
TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential signicant biomarkers. Cancer Chemother Pharmacol. 2016;78:685–95.
52.
Chae SY, Kim S-B, Ahn SH, etal. A randomized fea-
sibility study of 18F-uoroestradiol PET to predict
pathologic response to neoadjuvant therapy in estrogen receptor–rich postmenopausal breast cancer. J
Nucl Med. 2017;58:563–8.
Peterson LM, Kurland BF, Yan F, et al.
53.
18F-Fluoroestradiol PET imaging in a phase II
trial of Vorinostat to restore endocrine sensitivity in
ER+/HER2− metastatic breast cancer. J Nucl Med.
2021;62:184–90.
Su Y, Zhang Y, Hua X, etal. High-dose tamoxifen in
54.
high-hormone-receptor-expressing advanced breast
cancer patients: a phase II pilot study. Ther Adv Med
Oncol. 2021;13:1758835921993436.
Linden HM, Stekhova SA, Link JM, etal. Quantitative
55.
uoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast
cancer. J Clin Oncol. 2006;24:2793–9.
Liu C, Xu X, Yuan H, Zhang Y, Zhang Y, Song
56.
S, Yang Z. Dual tracers of 16α-[18F]uoro-17β
estradiol and [18F]uorodeoxyglucose for prediction
of progressionin patients with HR+/HER2-metastatic breast cancer.
Front Oncol. 2020;10:10.
57.
Bodapati S, Abraham P, Chen A, Guilbault D,
McDonald M, Matro J, Shatsky R, Obrzut S. 18F-FES
PET/CT improves the detection of Intraorbital metastases in estrogen-receptor-positive breast cancer:
two representative cases and review of the literature.
Tomography. 2022;8:1060–5.
58.
Boers J, Loudini N, Brunsch CL, Koza SA, de Vries
EFJ, Glaudemans AWJM, Hospers GAP, Schröder
CP.Value of 18F-FES PET in solving clinical dilemmas in breast cancer patients: a retrospective study. J
Nucl Med. 2021;62:1214–20.
van Kruchten M, Glaudemans AWJM, de Vries EFJ,
59.
Beets-Tan RGH, Schröder CP, Dierckx RA, de Vries
EGE, Hospers GAP.PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients
presenting with a clinical dilemma. J Nucl Med.
2012;53:182–90.
60.
Sun Y, Yang Z, Zhang Y, etal. The preliminary study
of 16α-[18F]uoroestradiol PET/CT in assisting the
individualized treatment decisions of breast cancer
patients. PLoS One. 2015;10:e0116341.
Yang Z, Xie Y, Liu C, Liu X, Song S, Zhang Y,
61.
Ge R, Wang B, Yang Z. The clinical value of 18
F-uoroestradiol in assisting individualized treatment decision in dual primary malignancies. Quant
Imaging Med Surg. 2021;11:3956965–3965.
Chae SY, Son HJ, Lee DY, Shin E, Oh JS, Seo SY, Baek
62.
S, Kim JY, Na SJ, Moon DH. Comparison of diagnostic sensitivity of [18F]uoroestradiol and [18F]
uorodeoxyglucose positron emission tomography/
computed tomography for breast cancer recurrence in
patients with a history of estrogen receptor-positive
primary breast cancer. EJNMMI Res. 2020;10:54.
Gupta M, Datta A, Choudhury PS, Dsouza M, Batra
63.
U, Mishra A. Can 18F-Fluoroestradiol positron
emission tomography become a new imaging standard in the estrogen receptor-positive breast cancer patient: a prospective comparative study with
free survival after Fulvestrant therapy
-
286
https://t.me/med1917
M. R. Ruggiero et al.
18F-Fluorodeoxyglucose positron emission tomography? World J Nucl Med. 2017;16:133–9.
Liu C, Gong C, Liu S, Zhang Y, Zhang Y, Xu X, Yuan
64.
H, Wang B, Yang Z. 18F-FES PET/CT inuences
the staging and Management of Patients with newly
diagnosed estrogen receptor-positive breast cancer: a
retrospective comparative study with 18F-FDG PET/
CT.Oncologist. 2019;24:e1277–85.
65.
Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou
V, Riedl CC, Lewis JS, Mauguen A. Head-to-head
evaluation of 18F-FES and 18F-FDG PET/CT in
metastatic invasive lobular breast cancer. J Nucl Med.
2021;62:326–31.
Wang Y, Ayres KL, Goldman DA, et al.
66.
18F-Fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of
the novel estrogen receptor-targeted therapeutic
GDC-0810: using an imaging biomarker to guide
drug dosage in subsequent trials. Clin Cancer Res.
2017;23:3053–60.
Lin FI, Gonzalez EM, Kummar S, et al. Utility of
67.
18F-uoroestradiol (18F-FES) PET/CT imaging as
a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving
Z-endoxifen therapy. Eur J Nucl Med Mol Imaging.
2017;44:500–8.
68.
Jager A, de Vries EGE, Der Houven van Oordt CWM,
Neven P, Venema CM, Glaudemans AWJM, Wang Y,
Bagley RG, Conlan MG, Aftimos P.A phase 1b study
evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the
estrogen receptor in metastatic breast cancer lesions
using 18F-FES PET/CT imaging. Breast Cancer Res.
2020;22:97.
Iqbal R, Yaqub M, Oprea-Lager DE, Liu Y, Luik AM,
69.
Beelen AP, Schuit RC, Windhorst AD, Boellaard R,
van Oordt CWMDH.Biodistribution of 18F-FES in
patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel
selective ER degrader. J Nucl Med. 2022;63:694–9.
70.
Tsujikawa T, Yoshida Y, Kudo T, Kiyono Y, Kurokawa
T, Kobayashi M, Tsuchida T, Fujibayashi Y, Kotsuji F,
Okazawa H.Functional images reect aggressiveness
of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET. J Nucl Med.
2009;50:1598–604.
71.
Tsujikawa T, Yoshida Y, Kiyono Y, Kurokawa T, Kudo
T, Fujibayashi Y, Kotsuji F, Okazawa H. Functional
oestrogen receptor α imaging in endometrial carcinoma using 16α-[18F]uoro-17β-oestradiol PET.Eur
J Nucl Med Mol Imaging. 2011;38:37–45.
Yoshida Y, Kiyono Y, Tsujikawa T, Kurokawa T,
72.
Okazawa H, Kotsuji F.Additional value of 16α-[18F]
uoro-17β-oestradiol PET for differential diagnosis
between uterine sarcoma and leiomyoma in patients
with positive or equivocal ndings on [18F]uorodeoxyglucose PET.Eur J Nucl Med Mol Imaging.
2011;38:1824.
73.
Zhao Z, Yoshida Y, Kurokawa T, Kiyono Y, Mori
T, Okazawa H. 18F-FES and 18F-FDG PET for
differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation
with Immunohistochemical analysis. J Nucl Med.
2013;54:499–506.
74.
van Kruchten M, de Vries EFJ, Arts HJG, Jager NM,
Bongaerts AHH, Glaudemans AWJM, Hollema H, de
EGE V, Hospers GAP, Reyners AKL.Assessment of
estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-Fluoro-17β-estradiol PET/
CT.J Nucl Med. 2015;56:50–5.
75.
Sieh W, Köbel M, Longacre TA, et al. Associations
between hormone receptor expression and ovarian
cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncol. 2013;14:853–62.
Yoshida Y, Kurokawa T, Tsujikawa T, Okazawa H,
76.
Kotsuji F. Positron emission tomography in ovarian
cancer: 18F-deoxy-glucose and 16alpha-18F-uoro17beta-estradiol PET.J Ovarian Res. 2009;2:7.
Hołody Ł, Kunikowska J, Braziewicz J.Simultaneous
77.
breast cancer and DLBCL lymphoma—role of PET/
CT examination with 18F-FDG and 18F-FES.Nucl
Med Rev. 2018;21:113–4.
Tsujikawa T, Yoshida Y, Maeda H, Tsuchida T, Mori T,
78.
Kiyono Y, Kimura H, Okazawa H.Oestrogen-related
tumour phenotype: positron emission tomography
characterisation with 18F-FDG and 18F-FES. Br J
Radiol. 2012;85:1020–4.
Venema CM, Apollonio G, Hospers GAP, Schröder
79.
CP, Dierckx RAJO, de Vries EFJ, Glaudemans
AWJM. Recommendations and technical aspects of
16α-[18F]Fluoro-17β-estradiol PET to image the
estrogen receptor invivo: the Groningen experience.
Clin Nucl Med. 2016;41:844–51.
80.
Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet
Y, Webner P, Divgi C, Linden HM.Whole-body characterization of estrogen receptor status in metastatic
breast cancer with 16α-18F-Fluoro-17β-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications.
Oncologist. 2020;25:835–44.
Paquette M, Lavallée É, Phoenix S, Ouellet R, Senta
81.
H, van Lier JE, Guérin B, Lecomte R, Turcotte
ÉE.Improved estrogen receptor assessment by PET
using the novel radiotracer 18F-4FMFES in estrogen
receptor–positive breast cancer patients: an ongoing
phase II clinical trial. J Nucl Med. 2018;59:197–203.
82.
Xu D, Zhuang R, You L, etal. 18F–labeled estradiol
derivative for targeting estrogen receptor-expressing
breast cancer. Nucl Med Biol. 2018;59:48–55.
Соседние файлы в папке Библиотека им академика М.И. Перельмана